Additive inhibitory effect of hydrocortisone and cyclosporine on low- density lipoprotein receptor activity in cultured HepG2 cells

Hepatology

Volumn 26, Issue 4, 1997, Pages 967-971

  Al Rayyes, Osama ^a,b   Wallmark, Anders ^a   Florén, Claes Henrik ^a  

^a Malmö University Hospital   (Sweden)

^b University Hospital Malmö   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUINDOSTATIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA;

ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL;

EID: 0030767547     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260425     Document Type: Article

References (25)

1. Bittar AE, Ratcliffe PJ, Richardson AJ, Raine AE, Jones L, Yudkin PL, Carter R, Mann JI, Morris PJ. The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy. Transplantation 1990;50:987-992.
2. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53:94-99.
3. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992;54: 868-871.
4. Ingulli E, Tejani A, Markell M. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children posttransplantation in the cyclosporine era. Transplantation 1993;55:1029-1033.
5. Montagnino G, Tarantino A, Aroldi A, Banfi G, Cesana B, Ponticelli C. Lipid profile in renal transplant recipients under various immunosuppressive regimens. Transplant Proc 1994;26:2634-2636.
6. Armstrong VW, Kaltefleiter M, Luy Kaltefleiter M, Schutz E, Wieland E, Loss M, Winkler M, Ringe B, Oellerich M. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. Transplant Proc 1995;27:1201-1203.
7. Gunnarsson R, Löfmark R, Nordlander R, Nyquist O, Groth C-G. Acute myocardial infarction in renal transplant recipients: incidence and prognosis. Eur Heart J 1984;5:218-221.
8. López-Miranda J, Pérez-Jiménez F, Torres A, Espino-Montoro A, Gomez P, Hidalgo-Rojas L, Ordovas MJ, et al. Effects of cyclosporine on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992;25:379-386.
9. Spiera H and Rothenberg RR. Myocardial infarction in four young patients with SLE. J Rheumatol 1983;10:464-466.
10. Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment. Am J Med 1986;80:925-929.
11. Ettinger WH, Goldberg AP, Applebaum-Bowden D. Dyslipoproteinemia in systemic lupus erythematosus. Am J Med 1987;83:503-508.
12. Havel RJ, Hamilton RL. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism. HEPATOLOGY 1988;8:1689-1704.
13. Javitt NB. HepG2 cells as a resource for metabolic studies: lipoproteins, cholesterol, and bile acids. FASEB J 1990;4:161-168.
14. Al Rayyes O, Wallmark A, and Florén C-H. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by 25%. HEPATOLOGY 1996;24:613-619.
15. Al Rayyes O, Wallmark A, Floŕn C-H. Reversal of cyclosporine inhibited low density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors. HEPATOLOGY 1997;25:991-994.
16. Kandus A, Kovac D, Kveder R and Bren AF. Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression. Transplant Proc 1994;26:2642-2643.
17. Vanhaecke J, Cleemput JV, Lierde JV, Daenen W, and Geest HD. Safety and efficacy of low-dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994;58:42-45.
18. Salter AM, Saxton J, Brindley D. Characterization of the binding of human low-density lipoprotein to primary monolayer cultures of rat hepatocytes. Biochem J 1986;240:549-557.
19. Ausubel MA, Bernt R, Kingston RE, Moore DD, Seidman JG, Smith JA, Strahl K. Preparation and analysis of RNA. In: Current Protocols in Molecular Biology. Cambridge: Green and Wiley, 1993:1:4.0.1-4.10.9.
20. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A 1989;86:9717-9721.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with folin phenol reagents. J Biol Chem 1951;193:265-275.
22. Afifi AA, Azen SP. Statistical Analysis. A Computer Oriented Approach (2nd ed.). New York: Academic, 1977.
23. Norusis MJ. SPSS for Windows, rel. 6.0. SPSS Inc., Chicago, IL, 1993.
24. Henze K, Chait A, Albers JJ, Bierman EL. Hydrocortisone decreases the internalization of low density lipoprotein in cultured human fibroblasts and arterial smooth muscle cells. Eur J Clin Invest 1983;13:171-177.
25. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use. JAMA 1988;260:239-241.